Jefferies Financial Group Weighs in on GlaxoSmithKline plc’s FY2019 Earnings (NYSE:GSK)

Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK) – Research analysts at Jefferies Financial Group increased their FY2019 EPS estimates for shares of GlaxoSmithKline in a research note issued on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford now expects that the pharmaceutical company will post earnings per share of $2.94 for the year, up from their previous forecast of $2.91. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q4 2019 earnings at $0.74 EPS, FY2020 earnings at $3.11 EPS, FY2021 earnings at $3.55 EPS and FY2022 earnings at $3.80 EPS.

A number of other equities research analysts have also recently commented on GSK. Morgan Stanley assumed coverage on in a research note on Monday, June 17th. They issued an “equal weight” rating and a GBX 215 ($2.81) target price on the stock. Zacks Investment Research raised Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Finally, Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and a consensus price target of $42.28.

NYSE GSK opened at $40.42 on Friday. GlaxoSmithKline has a 12 month low of $36.41 and a 12 month high of $42.32. The stock has a market capitalization of $101.53 billion, a PE ratio of 12.79, a P/E/G ratio of 2.12 and a beta of 0.74. The business has a fifty day moving average of $40.07. The company has a debt-to-equity ratio of 6.92, a quick ratio of 0.48 and a current ratio of 0.72.

GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.13. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%. The firm had revenue of $9.98 billion for the quarter, compared to analysts’ expectations of $9.86 billion.

The company also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were issued a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a yield of 4.90%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is 58.86%.

In other news, Director Plc Glaxosmithkline bought 325,000 shares of the stock in a transaction on Monday, April 22nd. The shares were bought at an average price of $18.00 per share, with a total value of $5,850,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders acquired 1,044,047 shares of company stock worth $16,249,991. 10.00% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of GSK. Norges Bank bought a new position in shares of GlaxoSmithKline in the fourth quarter worth about $17,275,000. Two Sigma Investments LP bought a new stake in GlaxoSmithKline during the 4th quarter valued at approximately $15,936,000. Deutsche Bank AG raised its stake in GlaxoSmithKline by 221.0% during the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after purchasing an additional 364,431 shares during the period. Millennium Management LLC raised its stake in GlaxoSmithKline by 612.0% during the 4th quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock valued at $13,959,000 after purchasing an additional 314,016 shares during the period. Finally, Foundry Partners LLC bought a new stake in GlaxoSmithKline during the 1st quarter valued at approximately $6,917,000. 11.26% of the stock is currently owned by institutional investors.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: What is the outlook for the FAANG stocks?

Earnings History and Estimates for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.